Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry

被引:15
|
作者
Matsuo, Ryu [1 ,2 ]
Kamouchi, Masahiro [2 ,3 ]
Fukuda, Haruhisa [2 ,3 ]
Hata, Jun [1 ,3 ]
Wakisaka, Yoshinobu [1 ]
Kuroda, Junya [1 ]
Ago, Tetsuro [1 ]
Kitazono, Takanari [1 ,3 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka 812, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Hlth Care Adm & Management, Fukuoka 812, Japan
[3] Kyushu Univ, Grad Sch Med Sci, Ctr Cohort Studies, Fukuoka 812, Japan
来源
PLOS ONE | 2014年 / 9卷 / 10期
关键词
RT-PA; TRIAL IST-3; MANAGEMENT; GREATER-THAN-OR-EQUAL-TO-80; ALTEPLASE; TPA;
D O I
10.1371/journal.pone.0110444
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives: The benefit of intravenous recombinant tissue plasminogen activator (rt-PA) therapy for very old patients with acute ischemic stroke remains unclear. The aim of this study was to elucidate the efficacy and safety of intravenous rt-PA therapy for patients over 80 years old. Methods: Of 13,521 stroke patients registered in the Fukuoka Stroke Registry in Japan from June 1999 to February 2013, 953 ischemic stroke patients who were over 80 years old, hospitalized within 3 h of onset, and not treated with endovascular therapy were included in this study. Among them, 153 patients were treated with intravenous rt-PA (0.6 mg/kg). For propensity score (PS)-matched case-control analysis, 148 patients treated with rt-PA and 148 PS-matched patients without rt-PA therapy were selected by 1:1 matching with propensity for using rt-PA. Clinical outcomes were neurological improvement, good functional outcome at discharge, in-hospital mortality, and hemorrhagic complications (any intracranial hemorrhage [ICH], symptomatic ICH, and gastrointestinal bleeding). Results: In the full cohort of 953 patients, rt-PA use was associated positively with neurological improvement and good functional outcome, and negatively with in-hospital mortality after adjustment for multiple confounding factors. In PS-matched case-control analysis, patients treated with rt-PA were still at lower risk for unfavorable clinical outcomes than non-treated patients (neurological improvement, odds ratio 2.67, 95% confidence interval 1.61-4.40; good functional outcome, odds ratio 2.23, 95% confidence interval 1.16-4.29; in-hospital mortality, odds ratio 0.30, 95% confidence interval 0.13-0.65). There was no significant association between rt-PA use and risk of hemorrhagic complications in the full and PS-matched cohorts. Conclusions: Intravenous rt-PA therapy was associated with improved clinical outcomes without significant increase in risk of hemorrhagic complications in very old patients (aged. 80 years) with acute ischemic stroke.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] A Stroke Registry Data on the Use of Intravenous Recombinant Tissue Plasminogen Activator in Stroke of Unknown Time of Onset
    Balogun, Ibrahim O.
    Brown, Aaron
    Bertoni, Miguel
    Webb, Thomas
    Hargroves, David
    Pullicino, Patrick
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2016, 25 (08): : 1843 - 1850
  • [42] Thrombolysis With Intravenous Tissue Plasminogen Activator Predicts a Favorable Discharge Disposition in Patients With Acute Ischemic Stroke
    Ifejika-Jones, Nneka L.
    Harun, Nusrat
    Mohammed-Rajput, Nareesa A.
    Noser, Elizabeth A.
    Grotta, James C.
    STROKE, 2011, 42 (03) : 700 - 704
  • [43] Outcome of Japanese Minor Stroke Patients Treated Without Intravenous Recombinant Tissue Plasminogen Activator Within 4.5 Hours After the Symptom Onset ∼Fukuoka Stroke Registry∼
    Fujimoto, Shigeru
    Osaki, Masato
    Kumamoto, Masaya
    Kanazawa, Makoto
    Tagawa, Naoki
    Ishitsuka, Takao
    Kitazono, Takanari
    STROKE, 2015, 46
  • [44] Intravenous tissue plasminogen activator in acute ischemic stroke: a two years experience
    Feuerhake, W
    Chamorro, H
    Araya, F
    REVISTA MEDICA DE CHILE, 1999, 127 (07) : 814 - 819
  • [45] Intravenous Tissue Plasminogen Activator Thrombolysis in Patients With Diabetes Mellitus and Previous Stroke
    Gonzalez-Hernandez, Ayoze N.
    Fabre-Pi, Oscar
    Lopez-Fernandez, Juan C.
    Diaz-Nicolas, Santiago
    STROKE, 2009, 40 (12) : E707 - E707
  • [46] Analysis of the Efficacy and Safety of Recombinant Tissue Plasminogen Activator for Chinese Patients over 80 Years of Age with Acute Ischemic Stroke: A Pilot Study
    Yang, Jiandao
    Liang, Huazheng
    Song, Yanyan
    Shen, Lingda
    Wang, Shaoshi
    NEUROSCIENCE BULLETIN, 2016, 32 (02) : 202 - 203
  • [47] Analysis of the Efficacy and Safety of Recombinant Tissue Plasminogen Activator for Chinese Patients over 80 Years of Age with Acute Ischemic Stroke: A Pilot Study
    Jiandao Yang
    Huazheng Liang
    Yanyan Song
    Lingda Shen
    Shaoshi Wang
    NeuroscienceBulletin, 2016, 32 (02) : 202 - 203
  • [48] RUPTURE OF AN OCCULT INTRACRANIAL MYCOTIC ANEURYSM AFTER INTRAVENOUS THROMBOLYSIS WITH RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE
    Glenn, Jared
    Strecker-McGraw, Margaret
    McGraw, Ian
    Jabbar, Karim
    James, Nathan A.
    Stone, C. Keith
    JOURNAL OF EMERGENCY MEDICINE, 2017, 53 (05): : 717 - 721
  • [49] Analysis of the Efficacy and Safety of Recombinant Tissue Plasminogen Activator for Chinese Patients over 80 Years of Age with Acute Ischemic Stroke: A Pilot Study
    Jiandao Yang
    Huazheng Liang
    Yanyan Song
    Lingda Shen
    Shaoshi Wang
    Neuroscience Bulletin, 2016, 32 : 202 - 203
  • [50] Are You Ever Too Old for Thrombolysis? Intravenous Recombinant Tissue Plasminogen Activator in Patients Age 80 and Older
    Chen, Shirley
    Barazangi, Nobl
    Rose, Jack
    Bedenk, Ann
    Phan, Jackie
    Tong, David
    NEUROLOGY, 2010, 74 (09) : A510 - A510